JP5922031B2 - 化合物 - Google Patents

化合物 Download PDF

Info

Publication number
JP5922031B2
JP5922031B2 JP2012544854A JP2012544854A JP5922031B2 JP 5922031 B2 JP5922031 B2 JP 5922031B2 JP 2012544854 A JP2012544854 A JP 2012544854A JP 2012544854 A JP2012544854 A JP 2012544854A JP 5922031 B2 JP5922031 B2 JP 5922031B2
Authority
JP
Japan
Prior art keywords
compound
syn
compounds
acid
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012544854A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013514980A5 (enExample
JP2013514980A (ja
Inventor
マスリア エリザー
マスリア エリザー
エム．ロッケンステイン エドワード
エム．ロッケンステイン エドワード
ウラシドロ ウォルフガング
ウラシドロ ウォルフガング
フリント ツィゲルニイ イゴル
フリント ツィゲルニイ イゴル
Original Assignee
ニューロポア セラピーズ，インコーポレイティド
ニューロポア セラピーズ，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニューロポア セラピーズ，インコーポレイティド, ニューロポア セラピーズ，インコーポレイティド filed Critical ニューロポア セラピーズ，インコーポレイティド
Publication of JP2013514980A publication Critical patent/JP2013514980A/ja
Publication of JP2013514980A5 publication Critical patent/JP2013514980A5/ja
Application granted granted Critical
Publication of JP5922031B2 publication Critical patent/JP5922031B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2012544854A 2009-12-16 2010-12-16 化合物 Expired - Fee Related JP5922031B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28708209P 2009-12-16 2009-12-16
US61/287,082 2009-12-16
PCT/US2010/060862 WO2011084642A1 (en) 2009-12-16 2010-12-16 Compound suitable for the treatment of synucleopathies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015218140A Division JP2016074679A (ja) 2009-12-16 2015-11-06 化合物

Publications (3)

Publication Number Publication Date
JP2013514980A JP2013514980A (ja) 2013-05-02
JP2013514980A5 JP2013514980A5 (enExample) 2014-02-13
JP5922031B2 true JP5922031B2 (ja) 2016-05-24

Family

ID=43629477

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012544854A Expired - Fee Related JP5922031B2 (ja) 2009-12-16 2010-12-16 化合物
JP2015218140A Withdrawn JP2016074679A (ja) 2009-12-16 2015-11-06 化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015218140A Withdrawn JP2016074679A (ja) 2009-12-16 2015-11-06 化合物

Country Status (12)

Country Link
US (2) US8846682B2 (enExample)
EP (1) EP2513090A1 (enExample)
JP (2) JP5922031B2 (enExample)
KR (1) KR20120112548A (enExample)
CN (1) CN102725284A (enExample)
AU (1) AU2010339841B2 (enExample)
BR (1) BR112012014807A2 (enExample)
CA (1) CA2784744A1 (enExample)
MX (1) MX335989B (enExample)
NZ (1) NZ600449A (enExample)
RU (1) RU2012129882A (enExample)
WO (1) WO2011084642A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2830608B8 (en) * 2012-03-28 2020-01-15 UCB Biopharma SRL Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation
US9284309B2 (en) * 2012-07-16 2016-03-15 Neuropore Therapies, Inc. Di- and tri-heteroaryl derivatives as inhibitors of protein aggregation
WO2014179303A1 (en) * 2013-04-29 2014-11-06 The General Hospital Corporation Amyloid precursor protein mrna blockers for treating down syndrome and alzheimer's disease
AU2015211119B2 (en) 2014-01-29 2019-05-30 Ucb Biopharma Sprl Heteroaryl amides as inhibitors of protein aggregation
CN104530013B (zh) * 2014-12-04 2016-06-29 中国农业大学 基于吲哚环的吡唑酰胺类化合物作为农用杀菌剂的用途
EP3328379B1 (en) * 2015-07-29 2021-07-28 UCB Biopharma SRL Bis-heteroaryl derivatives as modulators of protein aggregation
AU2018213886A1 (en) * 2017-01-26 2019-07-25 UCB Biopharma SRL Alkoxy bis-heteroaryl derivatives as modulators of protein aggregation
ES2882285T3 (es) * 2017-01-26 2021-12-01 Ucb Biopharma Sprl Derivados de bis-heteroarilo como moduladores de la agregación de proteínas
KR20190112022A (ko) * 2017-01-26 2019-10-02 유씨비 바이오파마 에스피알엘 단백질 응집의 조절제로서의 바이사이클릭 비스-헤테로아릴 유도체
US12178805B2 (en) 2017-05-11 2024-12-31 Remynd N.V. Inhibitors of PDE6Delta for use in the prevention and/or treatment of epilepsy and/or neurodegenerative disorders
WO2018206760A1 (en) 2017-05-11 2018-11-15 Remynd N.V. Compounds for the treatment of epilepsy, neurodegenerative disorders and other cns disorders
US20250074902A1 (en) * 2021-12-27 2025-03-06 Shanghai Jingxin Biomedical Co., Ltd. Fused bicyclic heteroaryl amide compound as protein aggregation inhibitor
TW202415651A (zh) 2022-07-29 2024-04-16 日商住友製藥股份有限公司 含氮飽和雜環衍生物
TW202412787A (zh) 2022-07-29 2024-04-01 日商住友製藥股份有限公司 2(1h)-吡啶亞胺衍生物
WO2024102758A2 (en) * 2022-11-08 2024-05-16 The General Hospital Corporation N-(n-aminoalkyl)phenanthridiunium series of chloride-sensitive fluorophores and methods of use thereof
WO2025002040A1 (zh) * 2023-06-25 2025-01-02 上海京新生物医药有限公司 双环杂芳基酰胺化合物的晶型及盐、制备方法和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0726263A3 (en) 1995-02-08 1996-10-09 American Cyanamid Co Herbicides (1,3,4) oxadiazoles and thiadiazoles
US5591695A (en) 1995-02-08 1997-01-07 American Cyanamid Co. Herbicidal [1,3,4]oxadiazoles and thiadiazoles
WO1998027108A2 (en) 1996-12-16 1998-06-25 Fujisawa Pharmaceutical Co., Ltd. New amide compounds and their use as nitric oxide synthase inhibitors
US6096688A (en) 1996-12-27 2000-08-01 American Cyanamid Company Oxazole carboxamide herbicides
JP2007519753A (ja) 2004-01-30 2007-07-19 スミスクライン ビーチャム コーポレーション 化合物
CA2580767A1 (en) * 2004-09-17 2006-03-30 Whitehead Institute For Biomedical Research Compounds, compositions and methods of inhibiting alpha-synuclein toxicity
DE102004051277A1 (de) 2004-10-21 2006-04-27 Merck Patent Gmbh Heterocyclische Carbonylverbindungen
KR101394245B1 (ko) * 2005-12-30 2014-05-14 에스케이바이오팜 주식회사 아이속사졸 유도체 및 이의 용도
US8541406B2 (en) * 2006-02-07 2013-09-24 Nv Remynd Thiadiazole derivatives for the treatment of neurodegenerative diseases
EP2007373A4 (en) * 2006-03-29 2012-12-19 Foldrx Pharmaceuticals Inc INHIBITION OF ALPHA SYNUCLEINE TOXICITY
US8163953B2 (en) * 2008-04-18 2012-04-24 University Of Connecticut Compounds for lysosomal modulation and methods of use
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
US8846682B2 (en) 2014-09-30
AU2010339841B2 (en) 2014-09-25
NZ600449A (en) 2014-10-31
BR112012014807A2 (pt) 2017-06-27
RU2012129882A (ru) 2014-01-27
US20130035342A1 (en) 2013-02-07
KR20120112548A (ko) 2012-10-11
JP2013514980A (ja) 2013-05-02
JP2016074679A (ja) 2016-05-12
EP2513090A1 (en) 2012-10-24
CN102725284A (zh) 2012-10-10
US20140364610A1 (en) 2014-12-11
MX335989B (es) 2016-01-07
WO2011084642A1 (en) 2011-07-14
AU2010339841A1 (en) 2012-07-05
CA2784744A1 (en) 2011-07-14
MX2012006740A (es) 2012-09-07

Similar Documents

Publication Publication Date Title
JP5922031B2 (ja) 化合物
RU2429237C2 (ru) N-(2-тиазолил)амидные производные в качестве ингибиторов gsk-3
WO2011156632A2 (en) Compositions and methods of treatment for tumors in the nervous system
EP1513836B1 (fr) Derives de piperazinylacylpiperidine, leur preparation et leur application en therapeutique
EP4234553A2 (en) Methods and compounds for the treatment of genetic disease
KR20150031481A (ko) 단백질 응집 저해제로서의 디- 및 트리-헤테로아릴 유도체
TWI415613B (zh) Anti-cancer agent resistance to overcome the agent
CN105611930A (zh) 作为非凋亡调控性细胞死亡抑制剂的螺环喹喔啉衍生物
TW202334148A (zh) 用於治療弗里德希氏共濟失調（ｆｒｉｅｄｒｅｉｃｈ＇ｓ ａｔａｘｉａ）之化合物及方法
AU2015207867A1 (en) Compounds and methods for the treatment of pain and other diseases
KR20150002713A (ko) 단백질 응집 저해제로서의 페닐-우레아 및 페닐-카바메이트 유도체
CN114667143A (zh) 用于预防或抑制轴突变性的组合物
CN114929675B (zh) 作为粘着斑激酶抑制剂的新型金刚烷衍生物
EP1699778B1 (fr) Derives de (4-phenylpiperazin-1-yl)acylpiperidine, leur preparation et leur application en therapeutique
EP4238567A1 (en) Novel treatment and prevention of sarcopenia-related diseases
TW202241892A (zh) 用於治療弗里德希氏運動失調症（ｆｒｉｅｄｒｅｉｃｈ＇ｓ ａｔａｘｉａ）之方法及化合物
US10538553B2 (en) Compounds for the treatment of neurodegenerative diseases
EP1694668B1 (fr) Derives de 4-[(arylmethyl)aminomethyl]piperidine, leur preparation et leur application en therapeutique
TWI857698B (zh) 作為組蛋白去乙醯酶6抑制劑之1,3,4-二唑三唑化合物及包含其之醫藥組合物
EP3079697B1 (en) Prolylhydroxylase/atf4 inhibitors for treating neural cell injury
AU2014271313A1 (en) Compound suitable for the treatment of synucleopathies
CN114790177B (zh) 新型Hedgehog信号通路抑制剂
JP6078153B2 (ja) チアンジンアミド誘導体、並びにその医薬組成物及び使用
CN118255740A (zh) 一种花青素-美金刚偶联物及制备方法和应用
WO2020253870A1 (zh) 具有a2a腺苷受体激动剂活性的6-肼基腺苷类化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141111

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20141113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150210

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20151110

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20151201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160202

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160301

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160309

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160413

R150 Certificate of patent or registration of utility model

Ref document number: 5922031

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees